Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors

Ovarian cancer is the fifth leading cause of cancer deaths. Chemoresistance, particularly against platinum compounds, contributes to a poor prognosis. Histone deacetylase inhibitors (HDACi) and heat shock protein 90 inhibitors (HSP90i) are known to modulate pathways involved in chemoresistance. This...

Full description

Bibliographic Details
Main Authors: Ana J. Rodrigues Moita, Jan J. Bandolik, Finn K. Hansen, Thomas Kurz, Alexandra Hamacher, Matthias U. Kassack
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:International Journal of Molecular Sciences
Subjects:
ovarian cancer
chemoresistance
HSP90 inhibitors
luminespib
HSP990
epigenetics
Online Access:https://www.mdpi.com/1422-0067/21/21/8300

Similar Items

Similar Items